(86 days)
Not Found
No
The description focuses on image processing and electro-tactile stimulation, with no mention of AI or ML algorithms for image interpretation or pattern generation. The device is described as having the same design and components as a previously cleared device, which also does not indicate the inclusion of AI/ML.
Yes
The device is intended to aid profoundly blind patients in orientation, mobility, and object recognition, which is a therapeutic purpose.
No
The device description indicates its purpose is to provide "electro-tactile stimulation to aid profoundly blind patients in orientation, mobility, and object recognition," which is a rehabilitative or assistive function, not a diagnostic one. It helps users perceive their environment, it does not identify or characterize a disease or condition.
No
The device description explicitly states it consists of hardware components: headset, controller, intra-oral device (IOD), and battery charger. It is described as a fully wearable, battery-operated device.
Based on the provided information, the BrainPort V100 is not an IVD (In Vitro Diagnostic) device.
Here's why:
- Intended Use: The intended use is to aid profoundly blind patients in orientation, mobility, and object recognition by providing electro-tactile stimulation to the tongue based on visual input. This is a direct interaction with the patient's sensory system for functional assistance, not for diagnosing a condition.
- Device Description: The device captures images and converts them into tactile stimulation patterns. It does not analyze biological samples (like blood, urine, or tissue) to provide diagnostic information.
- Anatomical Site: The device interacts with the tongue, which is a sensory organ, not a site for collecting samples for in vitro analysis.
- Performance Studies: The performance studies focus on cleaning/disinfection, electrical safety, biocompatibility, and software validation. These are typical for medical devices that interact with the body, but not specifically for validating diagnostic accuracy based on biological samples.
IVD devices are specifically designed to examine specimens derived from the human body to provide information for the diagnosis, prevention, monitoring, treatment, or alleviation of disease. The BrainPort V100 does not perform this function.
N/A
Intended Use / Indications for Use
The BrainPort V100 is an oral electronic vision aid that provides electro-tactile stimulation to aid profoundly blind patients in orientation, mobility, and object recognition as an adjunctive device to other assistive methods such as the white cane or a guide dog.
Product codes (comma separated list FDA assigned to the subject device)
PIC
Device Description
The BrainPort V100 design and components are the same as the previously granted BrainPort V100; the device continues to consist of the headset, controller (handset), intra-oral device (IOD), and battery charger. The camera unit in the headset captures the viewed scene as a digital image and forwards that image to the controller for processing. The IOD presents stimulation patterns representative of the camera image to the user's tongue. Same as in DEN130039, the BrainPort V100 is a fully wearable, battery operated device with no physical connections to external equipment during normal operation. The device includes a means for a sighted individual (e.g., instructor) to remotely view the camera and IOD images to assist in training through its vRemote software program.
Mentions image processing
The camera unit in the headset captures the viewed scene as a digital image and forwards that image to the controller for processing.
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Digital image from a camera unit.
Anatomical Site
User's tongue (for electro-tactile stimulation)
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
- Cleaning/Disinfection Validation: Cleaning and disinfection validation testing for the IOD component of the BrainPort V100 was conducted by an independent laboratory in accordance with guidelines outlined in AAMI TIR12:2010, AAMI TIR30:2011, ISO 17664:2004, ANSVAAMI ST81:2004(R)2010, and ANSI/AAMI ST58:2013. All results were passing, validating the cleaning and disinfection procedures. Results from performance testing also verified that the cleaning and disinfection procedures do not reduce electrode functionality.
- Electrical Safety and Electromagnetic Compatibility: Testing were conducted in accordance with the applicable standards IEC 60601-1, IEC 60601-1-2, and IEC 60601-1-11. Results were passing.
- Biocompatibility: The biocompatibility of the BrainPort V100 was established, and further supports the low risk of the BrainPort V100.
- Software: Software verification and validation testing was conducted, and results demonstrated that the software was appropriate for release.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Wicab, Inc. BrainPort V100 (DEN130039)
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 886.5905 Oral electronic vision aid.
(a)
Identification. An oral electronic vision aid is a battery-powered prescription device that contains an electrode stimulation array to generate electrotactile stimulation patterns that are derived from digital object images captured by a camera. It is intended to aid profoundly blind patients in orientation, mobility, and object recognition as an adjunctive device to other assistive methods such as a white cane or a guide dog.(b)
Classification. Class II (special controls). The special controls for this device are:(1) Clinical performance testing must demonstrate an acceptable adverse event profile, including adverse events involving the mouth, tongue, and gums and demonstrate the effect of the stimulation to provide clinically meaningful outcomes. The clinical performance testing must also investigate the anticipated conditions of use, including potential use error, intended environment of use, and duration of use.
(2) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use, including simulated moisture ingress, device durability, and battery reliability.
(3) Software verification, validation, and hazard analysis must be performed.
(4) Analysis/testing must validate electromagnetic compatibility.
(5) Analysis/testing must validate electrical safety.
(6) Analysis/testing must assess and validate wireless coexistence concerns.
(7) Any elements of the device that contact the patient must be demonstrated to be biocompatible.
(8) Training must include elements to ensure that the healthcare provider and user can identify the safe environments for device use, use all safety features of the device, and operate the device in the intended environment of use.
(9) Labeling for the trainer and user must include a summary of the clinical testing including adverse events encountered under use conditions, summary of study outcomes and endpoints, and information pertinent to use of the device including the conditions under which the device was studied (
e.g., level of supervision or assistance, and environment of use).
0
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
December 24, 2015
Wicab. Inc. c/o Steven B. Datlof, M.D., J.D. Partner Hogan Lovells US LLP 1835 Market Street, 2911 Floor Philadelphia, PA 19103
Re: K152851
Trade/Device Name: BrainPort V100 Regulation Number: 21 CFR 886.5905 Regulation Name: Oral electronic vision aid Regulatory Class: Class II Product Code: PIC Dated: September 29, 2015 Received: September 29, 2015
Dear Dr. Datlof:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
1
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801) medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Deborah L. Falls -S
for Malvina B. Eydelman, M.D. Director Division of Ophthalmic and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Indications for Use
Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement on last page
510(k) Number : K152851
Device Name
BrainPort V100
Indications for Use (Describe)
The BrainPort V100 is an oral electronic vision aid that provides electro-tactile stimulation to aid profoundly blind patients in orientation, mobility, and object recognition as an adjunctive device to other assistive methods such as the white cane or a guide dog.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number.
3
510(k) SUMMARY (K152851)
Wicab Inc.'s BrainPort V100
Submitter's Name, Address, Telephone Number, Contact Person and Date Prepared
Wicab. Inc. 8313 Greenway Blvd. Suite 100 Middleton, WI 53562 Phone: 608-829-4500 Facsimile: 608-829-4501 Contact Person: Robert Beckman, President and CEO
Date Prepared: December 21, 2015
Name of Device and Name/Address of Sponsor
BrainPort V100 Wicab, Inc. 8313 Greenway Blvd., Suite 100 Middleton, WI 53562
Common or Usual Name/Classification
Oral Electronic Vision Aid
21 CFR 886.5905, product code PIC, class II
Predicate/Reference Devices
Predicate Device: Wicab, Inc. BrainPort V100 (DEN130039)
Intended Use / Indications for Use
The BrainPort V 100 is an oral electronic vision aid that provides electro-tactile stimulation to aid profoundly blind patients in orientation, mobility, and object recognition as an adjunctive device to other assistive methods such as the white cane or a guide dog.
Technological Characteristics
The BrainPort V100 has the same intended use and indications for use as previously granted for the BrainPort V100 (DEN130039). In addition, the device has very similar technological characteristics and operating principles as the predicate. The BrainPort V100 design and components are the same as the previously granted BrainPort V100; the device continues to consist of the headset, controller (handset), intra-oral device (IOD), and battery charger. The
4
camera unit in the headset captures the viewed scene as a digital image and forwards that image to the controller for processing. The IOD presents stimulation patterns representative of the camera image to the user's tongue. Same as in DEN130039, the BrainPort V100 is a fully wearable, battery operated device with no physical connections to external equipment during normal operation. The device includes a means for a sighted individual (e.g., instructor) to remotely view the camera and IOD images to assist in training through its vRemote software program.
Similarities and differences from the predicate device are described below:
Modified IOD may be used by multiple users in the training period:
Similarities: No change in the IOD component. No change in how the user uses the device during and after the training period. Testing verified that there is no change in the electrode function of the modified device.
Differences: Validated cleaning and disinfection procedures, described below. If multiple users use the IOD during the training period, the BrainPort V100 device must be returned to Wicab for high level disinfection between users according to instructions provided in the device manual.
Minor software change:
Similarities: No change in how the device is used. The modified device functions in the same manner as the predicate device. Verification testing ensured that the updated software performs as intended.
Differences: Minor update changes the location of the audio .wav files. No other hardware or software changes were made.
Therefore, the technological characteristics of the device remain very similar to the device previously de novo granted in DEN130039.
Performance Data
Cleaning/Disinfection Validation: Cleaning and disinfection validation testing for the IOD component of the BrainPort V100 was conducted by an independent laboratory in accordance with guidelines outlined in AAMI TIR12:2010, AAMI TIR30:2011, ISO 17664:2004, ANSVAAMI ST81:2004(R)2010, and ANSI/AAMI ST58:2013. All results were passing, validating the cleaning and disinfection procedures. Results from performance testing also verified that the cleaning and disinfection procedures do not reduce electrode functionality.
Electrical Safety and Electromagnetic Electrical Safety/Electromagnetic Compatibility: Compatibility testing were conducted in accordance with the applicable standards IEC 60601-1, IEC 60601-1-2, and IEC 60601-1-11. Results were passing. There have been no changes in electronic hardware/technology compared to the predicate device.
5
Biocompatibility: The biocompatibility of the BrainPort V100 was established, and further supports the low risk of the BrainPort V100. There have been no changes to the device materials compared to the predicate.
Software: Software verification and validation testing was conducted, and results demonstrated that the software was appropriate for release.
Substantial Equivalence
The BrainPort V100 and the predicate device have the same intended use and indications for use. The BrainPort V100 system presents very similar technological characteristics and principles of operation as its predicate device. The minor difference in the software does not present any new types of safety or effectiveness questions since the BrainPort V100 performance and energy outputs remain the same. In addition, the cleaning and disinfection test reports validate the procedures for multiple patient use. Thus, the BrainPort V100 is substantially equivalent to its predicate (DEN130039).
Conclusions
The BrainPort V100 is substantially equivalent to its predicate device. Results from the cleaning and disinfection tests support multiple patient use of the BrainPort V100 during the training period. Furthermore, results from prior testing also demonstrate that the BrainPort V100 functions as intended. Therefore, Wicab believes the provided information is sufficient to demonstrate the substantial equivalence of the BrainPort V100 to its predicate device in support of clearance.